menu
    • menu
    [{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Levena Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ESG401","moa":"||Trop2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Levena Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Levena Biopharma \/ Levena Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Levena Biopharma \/ Levena Biopharma"},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||HIO","graph1":"Oncology","graph2":"Preclinical","graph3":"Levena Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Levena Biopharma \/ Navrogen","highestDevelopmentStatusID":"4","companyTruncated":"Levena Biopharma \/ Navrogen"},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"A166","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Levena Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Levena Biopharma \/ Sichuan Kelun-Biotech Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Levena Biopharma \/ Sichuan Kelun-Biotech Biopharmaceutical"},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Sichuan Kelun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"A166","moa":"||Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Levena Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Levena Biopharma \/ Levena Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Levena Biopharma \/ Levena Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Levena Biopharma

    Menu

    Levena Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Levena Biopharma

                            China arrow
                            EPSC
                            Not Confirmed

                            Levena Biopharma

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESG401,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Shanghai Escugen Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shanghai Escugen Biotechnology Co., Ltd., a Partner of Levena Biopharma, a Sorrento Company, Releases Positive...

                            Details : ESG401 is composed of a humanized anti-Trop2 IgG1 monoclonal antibody (mAb) conjugated to a topoisomerase I inhibitor SN38 via a proprietary stable covalent linker with a drug antibody ratio (DAR) of 8.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 06, 2023

                            Lead Product(s) : ESG401,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Shanghai Escugen Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Levena Biopharma

                            China arrow
                            EPSC
                            Not Confirmed

                            Levena Biopharma

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A166,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Sichuan Kelun-Biotech Biopharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candi...

                            Details : A166, a third-generation antibody-drug conjugate with tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock conjugation chemistry, demonstrated antitumor activity with meaningful responses in heavily pretreated subjects with HER2-posit...

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            March 05, 2022

                            Lead Product(s) : A166,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Sichuan Kelun-Biotech Biopharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Levena Biopharma

                            China arrow
                            EPSC
                            Not Confirmed

                            Levena Biopharma

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : A166,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Sichuan Kelun Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Pos...

                            Details : A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 06, 2022

                            Lead Product(s) : A166,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Sichuan Kelun Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Levena Biopharma

                            China arrow
                            EPSC
                            Not Confirmed

                            Levena Biopharma

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Navrogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Navrogen and Levena collaborate to Develop Antibody Drug Conjugates

                            Details : ADCs developed under this collaboration combine Levena’s linker and cytotoxic payload chemistry expertise along with Navrogen’s cancer-targeting antibodies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 02, 2020

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Navrogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth